BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Divi’s Laboratories Ltd., in addition to having a robust base business, is enhancing its product offerings in the generic active pharmaceutical ingredient space – at least sixteen molecules are under various phases of development and in the subsequent drug master file (DMF) filing stage.
Particularly, we find the company’s work interesting in the contrast media segment.
While there is complexity associated with Iodine-based products, the company’s strong chemistry skill set and experience in the contrast media space have enabled it to bring the Iohexol API to the validation phase.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR